We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Natural Tumor Suppressor Discovered

By Biotechdaily staff writers
Posted on 05 May 2005
A natural tumor suppressor that could potentially be triggered in specific cancers to prevent tumor growth has recently been discovered by scientists.

Situated on chromosome 18 and called PH domain leucine-rich repeat protein phosphatase (PHLPP, pronounced flip), researchers from the University of California, San Diego (UCSD, USA) showed that the tumor suppressor deletes a phosphate molecule, causing termination of cell-growth signaling by a protein called Akt that controls the balance between cell growth leading to tumor formation and cell death that prevents cancer.

"A drug that turns on PHLPP, so that it suppresses cell growth caused by Akt, could be a potential cancer therapy. More...
Currently, there are no compounds identified to directly stop Akt from causing cancer growth, once Akt signaling has been initiated,” said Alexandra C. Newton, Ph.D., professor of pharmacology at UCSD.

Researchers have known that Akt is important in controlling cell growth and death, and that it is linked to some of the most common human cancers. Even though one group of researchers found a molecule called PTEN, which prevents activation of Akt, no one as yet has determined how to exactly inactivate Akt one it has been activated.

Because the Akt molecule is secured in the "on” position when it has phosphate on it, the researchers figured that there must be another molecule that will pull off the phosphate and lock Akt in the "off” position. The UCSD team did a database search for the human genome for a phosphatase, which is an enzyme that acts as a catalyst in regulating cellular processes by removing phosphate molecules. Based on the chemical components of Akt, they looked for a phosphatase linked to the PH domain, a protein module found in a large variety of chemical signaling proteins in organisms ranging from yeast to humans.

Once they found PHLPP, which they found was expressed throughout the body, the UCSD team used cellular and biochemical data in human and other mammalian tissue to establish that PHLPP levels were considerably reduced in several colon cancer and glioblastoma cell lines that had increased Akt phosphorylation. Reintroduction of PHLPP into the cell lines caused a drastic suppression of tumor growth. With further laboratory testing, the team discovered that PHLPP blocks tumor growth by deleting a certain phosphate molecule at a position called Ser473 on Akt.

The scientists observed that PHLPP's role as a tumor suppressor could be applied to all cancers where Akt is elevated, "which is a large number of cancers,” stated Dr. Newton. The study was published in the April 1, 2005, issue of the journal Molecular Cell.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.